Allergic Reactions in Polio-Convalescent Children After Intracutaneous Injection of Heat-Inactivated Poliomyelitis Virus.

1931 ◽  
Vol 28 (9) ◽  
pp. 1072-1073 ◽  
Author(s):  
C. W. Jungeblut
1930 ◽  
Vol 30 (2) ◽  
pp. 221-238 ◽  
Author(s):  
Robert Philip ◽  
A. G. McKendrick ◽  
R. S. Begbie ◽  
W. O. Kermack ◽  
Donald Stewart

It will be convenient to summarise the results of the foregoing observations and the conclusions which appear justified by a comparison of results obtained by the two methods of standardisation under consideration, namely (1) cutaneous, on the human subject, and (2) intracutaneous (intradermal) on the guinea-pig.1. In the absence of knowledge regarding the essential chemistry of tuberculin, a chemical method of standardisation is excluded.2. The phenomena of allergic reactivity point to a biological basis for standardisation.3. The allergic reactions have been studied in the sensitised animal and in the human tuberculised subject.4. Tuberculins of unknown potency have been compared with a tuberculin of known potency which has been selected as standard.5. Comparative observations have been made as between the standard and the unknown tuberculin, by (a) making use of different dilutions, and (6) assessing results in animals (sensitised) and in human (tuberculised) subjects.6. In the sensitised guinea-pig the intracutaneous method has been used, and a definite procedure followed in the determination of results.7. In the human tuberculised subject the cutaneous method has been used, and similar procedure followed for the determination of results. The method and results are illustrated in the text.8. The results in the two sets of observations are definite and comparable. Both afford a basis for standardisation.9. The average probable errors by the two methods are approximately equal, that is, the accuracy of the one method is approximately equal to that of the other.10. If this be so, a strong plea may be advanced in favour of the human test. Shortly expressed: human (tuberculised) subjects are readily available for observation. The procedure involves little preparation, and the results are easily read with exactness. The tuberculin under test is to be used thereafter in relation to the human subject. This fact enhances the value of the test observations.If it be objected that in intracutaneous injection the amount of tuberculin introduced is measured more precisely, it may fairly be maintained that the droplet application of tuberculin is limited to a sharply defined area of skin surface and, further, that the clear skin of the human subject allows of more accurate estimation of the diameters of the areas of reaction.The present enquiry has shown that assays on a variety of human (tuberculised) subjects yield consistent results, and similarly, assays on various animals give consistent results. Yet the animal results are not always contistent with the human results. The explanation of the discrepancy is not very clear. It is not impossible that certain strains of tuberculin act in less degree on the human subject and in greater degree on the animal, and conversely. The occurrence of such differences might be misleading and even involve risk, if standardisation tests were limited to animals without control from observations on the human subject.If we grant, as the records have shown, that the procedure in relation to the human subject is sound and is innocuous to the human subject of the test, much may be said for the simplicity of the method and for the clarity of results obtained. As the tuberculins under test are destined for use on human subjects—for diagnostic and therapeutic purposes—it would seem reasonable, and probably safer, to base the standardisation of tuberculin (for human purposes) on observations in relation to man.


Author(s):  
E.Y. Chi ◽  
M.L. Su ◽  
Y.T. Tien ◽  
W.R. Henderson

Recent attention has been directed to the interaction of the nerve and immune systems. The neuropeptide substance P, a tachykinnin which is a neurotransmitter in the central and peripheral nervous systems produces tissue swelling, augemntation of intersitial fibrin deposition and leukocyte infiltration after intracutaneous injection. There is a direct correlation reported between the extent of mast cell degranulation at the sites of injection and the tissue swelling or granulocyte infiltration. It has previously been demonstrated that antidromic electrical stimulation of sensory nerves induces degranulation of cutaneous mast cells, cutaneous vasodilation and augmented vascular permeability. Morphological studies have documented a close anatiomical association between mast cells and nonmyelinated nerves, that contain substance P and other neuropeptides. However, the presence of mast cells within nerve fasicles has not been previously examined ultrastructurally. In this study, we examined ultrastructurally the distribution of mast cells in the nerve fiber bundles located in the muscular connective tissue of rat tongues (n=20).


2011 ◽  
Vol 81 (23) ◽  
pp. 173-180 ◽  
Author(s):  
Barbara K. Ballmer-Weber

Four to eight percent of the population are estimated to be food-allergic. Most food allergies in adolescents and adults are acquired on the basis of cross-reaction to pollen allergens. Theses allergens are ubiquitous in the plant kingdom. Therefore pollen-allergic patients might acquire a multitude of different plant food allergies, and even react to novel foods to which they have never previously been exposed. A curative therapy for food allergy does not yet exist. Food-allergic patients have to rely on strict avoidance diets, The widespread use of industrially processed foods poses a general problem for food-allergic patients. Although the most frequent allergens must be declared openly in the list of ingredients, involuntary contamination with allergy-provoking compounds can occur. The precautionary labelling “may contain” is sometimes applied even if the chance of contamination is very low; on the other hand, foods not declared to contain possible traces of allergenic components may actually contain relevant amounts of allergenic proteins. Switzerland is the only country in Europe with legal regulations on contamination by allergenic food; however, the allowance of 1 g/kg is too high to protect a relevant proportion of food-allergic individuals.


2009 ◽  
Vol 29 (02) ◽  
pp. 155-157 ◽  
Author(s):  
H. Hauch ◽  
J. Rischewski ◽  
U. Kordes ◽  
J. Schneppenheim ◽  
R. Schneppenheim ◽  
...  

SummaryInhibitor development is a rare but serious event in hemophilia B patients. Management is hampered by the frequent occurrence of allergic reactions to factor IX, low success rates of current inhibitor elimination protocols and the risk of development of nephrotic syndrome. Single cases of immune tolerance induction (ITI) including immunosuppressive agents like mycophenolat mofetil (MMF) or rituximab have been reported. We present a case of successful inhibitor elimination with a combined immune-modulating therapy and high-dose factor IX (FIX). This boy had developed a FIX inhibitor at the age of 5 years and had a history of allergic reactions to FIX and to FEIBA→. Under on-demand treatment with recombinant activated FVII the inhibitor became undetectable but the boy suffered from multiple joint and muscle bleeds. At the age of 11.5 years ITI was attempted with a combination of rituximab, MMF, dexamethasone, intravenous immunoglobulins and high-dose FIX. The inhibitor did not reappear and FIX half-life normalized. No allergic reaction, no signs of nephrotic syndrome and no serious infections were observed.


1974 ◽  
Vol 32 (02/03) ◽  
pp. 468-482 ◽  
Author(s):  
O Storm ◽  
P Ollendorff ◽  
E Drewsen ◽  
P Tang

SummaryThe thrombolytic effect of pig plasmin was tested in a double blind trial on patients with deep venous thrombosis in the lower limb. Only patients with not more than three days old thrombi were selected for this study. The diagnosis of deep vein thrombosis was made clinically and confirmed by phlebography. Lysofibrin Novo (porcine plasmin) or placebo (porcine plasminogen) was administered intravenously to the patients. The enzyme and the placebo were delivered as lyophilized powder in labelled bottles - the contents of the bottles were unknown to the doctor in charge of the clinical administration of the trial. An initial dose of plasmin/plasminogen of 30 unit per kg body weight given slowly intravenously (1-1% hours infusion) was followed by a maintenance dosis of 15 per cent the initial dose per hour for the following 5-7 hours. In most cases a similar maintenance dosis was given the next day. In all patients heparin was administered after ending the plasmin/plasminogen infusion. The results of the treatment was evaluated clinically as well as by control phlebo- grams the following days.A statistically significant improvement was found in the plasmin treated group compared with the placebo (plasminogen) treated group. Thrombolysis was obtained clinically and phlebographically in 65 per cent of the plasmin treated group, but only in 15 per cent of the control patients were improvements found.This study has thus demonstrated that plasmin treatment according to a standard scheme was able to induce thrombolysis. There were only a few and insignificant side effects. Allergic reactions have not been seen and only very simple tests are required.


Sign in / Sign up

Export Citation Format

Share Document